Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

GlobeNewswire October 6, 2020

Affimed to Present at Jefferies Virtual Cell Therapy Summit

GlobeNewswire September 29, 2020

Affimed to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2020

Affimed Reports Second Quarter 2020 Financial Results and Operational Progress

GlobeNewswire August 11, 2020

Affimed Announces Two New Appointments to Its Supervisory Board

GlobeNewswire August 5, 2020

Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

GlobeNewswire August 4, 2020

Affimed Announces Annual General Meeting of Shareholders

GlobeNewswire July 10, 2020

Affimed Reports First Quarter 2020 Financial Results and Operational Progress

GlobeNewswire June 23, 2020

Affimed Announces Presentation of Data on Genentech's RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed's ROCK® Platform, at AACR Virtual Annual Meeting II

GlobeNewswire June 22, 2020

Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

GlobeNewswire June 17, 2020

Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference

GlobeNewswire June 16, 2020

Affimed Announces Appointment of Angus Smith as Chief Financial Officer

GlobeNewswire June 11, 2020

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

GlobeNewswire May 29, 2020

Affimed to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 28, 2020

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

GlobeNewswire May 15, 2020

Affimed Reports 2019 Financial Results and Recent Operational Progress

GlobeNewswire April 28, 2020

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

GlobeNewswire April 16, 2020

Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

GlobeNewswire April 2, 2020

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

GlobeNewswire April 1, 2020

Affimed Announces Participation at Upcoming Virtual Investor Conferences

GlobeNewswire March 26, 2020